NASDAQ: ABCL

AbCellera Biologics (ABCL) Stock Analysis & Forecast

Nov 13 close

$11.49−0.13 (−1.1%)

Gekko Brief

AI summaryNov 9 close

AbCellera reports third-quarter results, with a loss that tops revenue estimates and compares to a loss of $0.19 per share a year ago. Investor attention centers on ABCL635, the antibody targeting vasomotor symptoms in postmenopausal women, following positive Phase 2 data that management and observers describe as a crucial clinical signal for the company's antibody discovery platform. The company also announced it will present at the UBS Global Biopharma Conference on 17 November 2026.

Shares close at $12.50, up 5.2%, sitting above both the 50-day average of $12.30 and the 200-day average of $7.08, with the 50-day above the 200-day. The GekkoIndex reads 57.6, placing the stock in the Neutral zone after slipping 3 points over five sessions. Gekko Fair Value stands at $14.24, putting the current price 12.2% below that mark. One-year return sits at 175.9%, though the one-month return is slightly negative at -0.4%.

No confirmed earnings date currently appears on the calendar, following the last report on 5 August 2026, which beat estimates and produced a 7.2% reaction. Over the last 90 days, 4 open-market insider purchases totaling $1,545,679 have been recorded, alongside 1 unusual options signal in the last 30 days, with call premium of $280,416 and no put premium. Analyst coverage from 7 firms shows 6 buy ratings, 1 hold, and a consensus target of $17.17. Seasonality over the next 20 trading days has averaged -0.8% across 5 years, rising in 2 of them.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

AbCellera Biologics price vs fair value

$14.58$11.49Nov ’25May ’26Nov ’26
Close $11.49200-day averageGekko Fair Value $14.58

AbCellera Biologics quick facts

Market cap
$3.75B
P/E ratio
—
Forward P/E
27.6
EPS, TTM
−$0.48
Revenue, TTM
$66.17M
Profit margin
-248.8%
Dividend yield
—
Beta
1.59
Volume
2.62M avg 3.18M
1-year return
+189.4%
Typical daily move
±9.2%
Typical 20-day move
±11.8%
50-day average
$12.34
200-day average
$7.24
Next earnings
Feb 23 after close
Shares outstanding
326.6M
52-week range
$2.75$15.02

AbCellera Biologics swing-trade checklist

AbCellera Biologics scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $11.49 sits between the 50-day ($12.34) and 200-day ($7.24) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    60.2, Accumulation

    Reading 60.2 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    21.2% below

    Price is 21.2% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 4 open-market insider purchases. Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −7.3% on average

    From this point in the calendar, the next 20 trading days averaged −7.3% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

AbCellera Biologics stock chart and price history

AbCellera Biologics closed at $11.49 on Nov 13, 2026, +189.4% over the past year, inside a 52-week range of $2.75 to $15.02.

Close50-day average200-day averageVolume
AbCellera Biologics share price, past year, with 50-day and 200-day moving averages and volume$5$10$15DecJan 2026FebMarAprMayJunJulAugSepOctNov11.49

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−9.4%
3 months
+2.6%
6 months
+180.9%
1 year
+189.4%
The full ABCL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABCL in Gekko

Follow AbCellera Biologics through every session

Put ABCL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ABCL in GekkoFree for 7 days. No credit card required.

About AbCellera Biologics

AbCellera Biologics develops a technology platform aimed at finding antibodies that can be turned into new pharmaceutical drugs. The system relies on artificial intelligence to study natural immune responses and pick out antibody candidates with therapeutic potential. This search-and-discovery work for drug-worthy antibodies is the core of what the company is recognized for.

The business operates through discovery programs carried out with outside partners, some finished and others still underway or under contract. As of the end of 2021 it had built up 156 such programs across 36 partner organizations. Among these relationships is a research collaboration and license agreement with Eli Lilly and Company, which stands out as a named partner in its work.

AbCellera was founded in 2012 and is based in Vancouver, Canada. Its shares are listed on the NASDAQ under the ticker ABCL.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
abcellera.com

AbCellera Biologics GekkoIndex: the smart money zone

AbCellera Biologics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.2, in the Accumulation zone, up 0.8 points over five sessions.

010060.2Accumulation

Up 0.8 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying42−0.4%+1.4%+0.3%−7.1%
Accumulation (current zone)241+1.7%+4.6%+10.7%+16.6%
Neutral362+1.2%+1.5%+1.8%+15.4%
Distribution47−0.4%+0.8%+6.9%+13.9%
Selling10+5.4%+6.3%+3.7%+0.8%

Average ABCL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the ABCL price, zone by zone.Track ABCL in Gekko

Is AbCellera Biologics stock overvalued? Gekko Fair Value

AbCellera Biologics trades 21.2% below Gekko Fair Value of $14.58, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what AbCellera Biologics shares are worth, recalculated every trading day.

$14.58

Gekko Fair Value, Nov 14, 2026

21.2% Undervalued

At the end of Aug 2026 the price was 17.5% below the estimate.

Gekko Fair ValueShare price, month end
$15$11Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ABCL in Gekko

AbCellera Biologics insider and Congress trading

Insiders filed 4 open-market purchases in AbCellera Biologics worth $1.48M, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$1.48Min 4 open-market purchases

FiledInsiderTypeSharesValue
Nov 13Booth Andrew
officer: Chief Financial Officer
Purchase8,600$97K
Nov 12Thermopylae Holdings Ltd.
10 percent owner
Purchase60,565$699K
Aug 24Hayden Michael R
director
Purchase53,613$570K
Aug 18John S. Montalbano
Director
Purchase10,000$110K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in ABCL were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ABCL, plotted on the chart in Gekko.Open ABCL in Gekko

Buybacks

AbCellera Biologics has been buying back its own shares.

Bought back, quarter ended Dec 31, 2024
$1.58M
As a share of market cap
0.04%

From company filings.

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Oct 20, $280K in unusual premium.

Every signal with its contract, strike and premium.Unlock in Gekko

AbCellera Biologics earnings: next date and track record

AbCellera Biologics reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±6.9%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−11.3%Feb ’25+1.0%May ’25+3.2%Aug ’25−16.6%Nov ’25+5.3%Feb ’26−5.5%May ’26+7.2%Aug ’26+4.9%Nov ’26

Last earnings call, Nov 9, 2026 AI summary

What they said
AbCellera's Q3 2026 was highlighted by positive Phase 2 results for ABCL635, an investigational antibody for non-hormonal treatment of vasomotor symptoms (hot flashes). A single 600mg injection achieved 83% reduction in daily hot flash frequency vs. 33% placebo, a 50% placebo-adjusted difference. 37% of ABCL635 patients achieved complete resolution vs. 2.2% placebo. Management views results as potentially category-defining in women's health.
Guidance
AbCellera is fully committed to advancing ABCL635 into late-stage development in 2024, citing significantly expanded commercial prospects. No specific revenue or earnings targets were provided in this excerpt.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 9, 2026−$0.13
est −$0.17
+23.8%$10.64M
est $8.42M
+26.4%+4.9%
Aug 5, 2026−$0.18
est −$0.17
−5.9%$4.05M
est $7.85M
−48.4%+7.2%
May 11, 2026−$0.14
est −$0.20
+30.0%$8.32M
est $5.41M
+53.6%−5.5%
Feb 24, 2026−$0.03
est −$0.14
+79.2%$44.90M
est $6.67M
+572.9%+5.3%
Nov 6, 2025−$0.19
est −$0.17
−11.8%$8.96M
est $6.31M
+41.9%−16.6%
Aug 7, 2025−$0.12
est −$0.17
+29.4%$17.08M
est $6.36M
+168.6%+3.2%
May 8, 2025−$0.15
est −$0.17
+11.8%$4.24M
est $7.31M
−42.1%+1.0%
Feb 27, 2025−$0.11
est −$0.15
+26.7%$5.05M
est $7.58M
−33.4%−11.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

AbCellera Biologics stock forecast and analyst price targets

Analysts’ average 12-month price target for AbCellera Biologics is $18.00, +56.7% from the last close, from 9 firms rating the stock in the last 90 days.

$18.00consensus 12-month target, +56.7% from the last close
Low $14High $30
Buy8
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12UBSBuy, maintained$18+56.7%
Nov 10Stifel NicolausBuy, reiterated$14+21.8%
Nov 10J.P. MorganBuy, maintained$17+48.0%
Nov 10JonesTradingBuy, maintained$25+117.6%
Nov 10BMO CapitalBuy, reiterated$15+30.5%
+10.7%average 20-day move after past Accumulation readings
−7.3%average move over the next 20 trading days in the last 5 years
±9.2%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

AbCellera Biologics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, AbCellera Biologics averaged −7.3% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−19.7%2021−29.4%2022+16.4%2023+1.8%2024−4.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−5.3%1 of 5
Next 10 trading days−1.6%2 of 5
Next 15 trading days−4.7%1 of 5
Next 20 trading days−7.3%2 of 5
Next 30 trading days−3.3%2 of 5

For scale, ABCL’s typical 20-trading-day move in either direction is about 11.8%.

AbCellera Biologics market cap and key statistics

AbCellera Biologics’s market cap is $3.75B and revenue of $66.17M over the last twelve months.

Valuation

Market cap
$3.75B
Forward P/E
27.6
EPS, TTM
−$0.48
Gekko Fair Value
$14.58

Trading

Volume
2.62M
Avg volume, 20 days
3.18M
52-week high
$15.02
52-week low
$2.75
Shares outstanding
326.6M

Financials

Revenue, TTM
$66.17M
Profit margin
-248.8%
Return on equity
-17.3%
Quarterly earnings growth, YoY
+45.9%

Risk and income

Beta
1.59
Typical daily move
±9.2%
Typical 20-day move
±11.8%

AbCellera Biologics peers

AbCellera Biologics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

AbCellera Biologics stock FAQ

What is AbCellera Biologics’s market cap?

AbCellera Biologics’s market cap is $3.75B at the Nov 13, 2026 close of $11.49, with 326.6M shares outstanding.

What is the AbCellera Biologics stock forecast?

The consensus analyst 12-month price target for AbCellera Biologics is $18.00, +56.7% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is AbCellera Biologics stock overvalued or undervalued?

On Gekko’s estimate AbCellera Biologics is undervalued: the Nov 13, 2026 close of $11.49 is 21.2% below Gekko Fair Value of $14.58. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does AbCellera Biologics report earnings next?

AbCellera Biologics is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of −$0.18 per share on revenue of $7.28M. AbCellera Biologics beat the earnings estimate in 6 of its last 8 reports, moving 6.9% on average across the report.

What is AbCellera Biologics’s 52-week high and low?

AbCellera Biologics’s 52-week high is $15.02 and its 52-week low is $2.75; it closed at $11.49 on Nov 13, 2026, +189.4% over the past year. Over the last five years the shares peaked at $16.77 on Nov 15, 2021.

Is AbCellera Biologics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in AbCellera Biologics?

Gekko flagged 1 unusual options signal in AbCellera Biologics over the last 30 days, with $280K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 20, 2026 with $280K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See AbCellera Biologics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.